B7981032 - A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
This research is a phase 3 study, which means it's one of the final steps before a new medicine might become widely available. It's designed to understand how safe and effective a drug called Ritlecitinib is for people aged 18 and over who have alopecia areata. Alopecia areata causes hair loss, usually in patches. Participants will take the new medicine, and doctors will carefully check for any side effects and see how their hair growth changes over a long period. The main goal is to make sure the medicine is safe and to see if it helps reduce hair loss.
Auf einen Blick
Worum geht es in dieser Studie?
This study is focusing on a new medicine called Ritlecitinib for people who have alopecia areata. Alopecia areata is a condition where your immune system, which normally fights off germs, mistakenly attacks your hair follicles, leading to hair loss. This new medicine aims to calm down that immune reaction.
The main purpose of this study is to find out if Ritlecitinib is safe to use over a long time and how well it works to help people with alopecia areata. Researchers will be especially looking at any unwanted effects, also known as side effects, that people might experience while taking the medicine. They'll also be regularly checking participants' health, including vital signs like blood pressure and heart rate, and doing blood tests.
Another key part of the study is to see how much hair grows back. They will use a special scoring system to measure hair loss and regrowth. This study is important because it could lead to a new treatment option for people living with alopecia areata, helping to improve their hair health and overall well-being.
Wichtige Erkenntnisse
- This study evaluates a new medicine, Ritlecitinib, for alopecia areata.
- It's a long-term study to check for safety and effectiveness.
- Open to adults aged 18 and older with alopecia areata.
- Participants will receive the active study medicine.
- Regular health checks and hair growth measurements will be done.
Wer könnte berechtigt sein?
This study is open to adults aged 18 and older. Both men and women are welcome to take part in the research.
To be considered for this study, you must have alopecia areata. The study doctors will carefully check your medical history and conduct an examination to make sure the study is right for you.
There might be other specific health requirements or conditions that would prevent you from joining. These will be discussed in detail with the study team to ensure your safety and that the results of the study are clear.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Do you have a diagnosis of alopecia areata?
- Are you able to attend regular clinic appointments for over three years?
- Are you willing to take a new study medicine?
- Sind Sie mit Bluttests und körperlichen Untersuchungen einverstanden?
Was beinhaltet die Teilnahme?
If you join this study, you will be taking the new medicine, Ritlecitinib. This is an "open-label" study, which means both you and the study doctors will know you are receiving the active medicine. The study involves regular visits to the clinic over a long period, potentially longer than three years.
During these visits, the study team will carry out various checks. This will include taking your vital signs (like temperature, blood pressure, and heart rate), taking blood samples for lab tests, and carefully asking about any health changes or side effects you might be experiencing. They will also measure your hair growth using a special tool to track how well the medicine is working. You will have a final check-up visit about 28 days after your last dose of the study medicine.
Potenzielle Risiken und Vorteile
Standorte (4)
- —UnbestätigtDeutschland
- —UnbestätigtSpanien
- —UnbestätigtPolen
- —UnbestätigtTschechien
Häufige Fragen
Was ist Alopecia Areata?
Alopecia areata is a condition where your immune system mistakenly attacks your hair follicles, causing hair to fall out, often in patches.
What is Ritlecitinib?
Ritlecitinib is the name of the new medicine being tested in this study. It's designed to help calm the immune system reaction that causes hair loss in alopecia areata.
Wie lange wird die Studie dauern?
This is a long-term study, and participants will be followed for over three years to understand the medicine's effects over time.
Will I know if I'm getting the active medicine?
Yes, this is an "open-label" study, meaning everyone involved, including you, will know you are receiving Ritlecitinib.
What kind of tests will I have during the study?
You'll have regular check-ups, including vital signs, blood tests, and measurements of your hair growth to see how the medicine is working.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.